Dianne C. Whitfield, Chief Human Sources Officer at Tarsus Prescribed drugs (NASDAQ:TARS), reported the direct sale of 12,274 shares of widespread inventory in a number of open-market transactions between March 17 and March 19, 2026, as disclosed within the SEC Kind 4 submitting.
|
Metric |
Worth |
|---|---|
|
Shares offered (direct) |
12,274 |
|
Transaction worth |
~$839,000 |
|
Submit-transaction widespread shares (direct) |
35,028 |
|
Submit-transaction worth (direct possession) |
~$2.34 million |
Transaction worth primarily based on SEC Kind 4 weighted common buy value ($68.36); post-transaction worth primarily based on trade-date shut value as per SEC Kind 4 submitting.
-
How does this sale evaluate to Whitfield’s prior insider transactions at Tarsus Prescribed drugs?
The 12,274 shares offered exceeded the median insider sale of 9,835 shares over the previous 12 months, although it’s consistent with her current sample of decreasing holdings in increments that replicate out there share capability. -
What quantity of her total place did Whitfield scale back on this transaction?
This sale represented 25.95% of her direct holdings on the time, as reported within the submitting, bringing her direct share rely from 47,302 to 35,028. -
Was this transaction linked to any oblique entities or spinoff workout routines?
All shares traded have been held straight by Whitfield; there have been no gross sales from trusts, LLCs, or by way of spinoff safety workout routines. -
What’s the context for timing and market pricing of those gross sales?
The weighted common sale value was round $68.36 per share, in comparison with a closing value of $66.75 on March 19, 2026; over the previous 12 months, Tarsus Prescribed drugs shares had a complete return of twenty-two.48% as of the transaction date.
|
Metric |
Worth |
|---|---|
|
Worth (as of market shut 3/19/26) |
$68.36 |
|
Market capitalization |
$2.73 billion |
|
Income (TTM) |
$451.36 million |
|
Internet revenue (TTM) |
-$66.42 million |
* 1-year efficiency is calculated utilizing March nineteenth, 2026 because the reference date.
-
Tarsus Prescribed drugs develops and commercializes novel therapeutics for ophthalmic and different illnesses, with its lead product TP-03 focusing on Demodex blepharitis and meibomian gland illness; extra pipeline property embody TP-04 for rosacea and TP-05 for Lyme prophylaxis and malaria discount.
-
Tarsus targets ophthalmologists, dermatologists, and healthcare suppliers treating eye and pores and skin illnesses, with a concentrate on sufferers affected by Demodex-related circumstances and different underserved indications.
Tarsus Prescribed drugs operates on the intersection of biotechnology and ophthalmology, specializing in unmet medical wants in eye care and associated fields. The corporate’s technique facilities on advancing first-in-class therapeutics by way of late-stage medical growth and commercialization. Its aggressive edge lies in a differentiated pipeline addressing high-prevalence circumstances with restricted remedy choices, supported by a specialised industrial infrastructure.
